---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-029221"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:47:05.241724+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncology Institute Q3 revenue $65M (+24% YoY); cuts FY2022 guidance on slower acquisitions

## Summary
- Net loss $2.7M ($0.03 basic loss per share); adjusted EBITDA -$7M vs +$0.1M prior year.
- Revenue guidance cut to $245-250M from $270-310M; adjusted EBITDA guidance lowered to -$28M to -$25M.
- Completed $110M strategic investment via senior convertible notes from Deerfield on August 9, 2022.
- Ended Q3 with 100 clinicians (+27% YoY); expanded to 14 markets with three acquisitions and two de novo clinics.
- Workforce reduction and vendor cost-cutting initiated to align cost structure with revenue growth.

## SEC filing metadata
- accession: 0001628280-22-029221
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/0001628280-22-029221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/toi-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-029221
- JSON: https://secwatch.observer/filing/0001628280-22-029221.json
- Plain text: https://secwatch.observer/filing/0001628280-22-029221.txt

## Key facts
- Earnings Releases
  Oncology Institute, Inc. reported three months ended September 30, 2022 results: revenue $65 million, net income Net loss of $2.7 million, EPS $(0.03). Guidance raised.
  - Period: three months ended September 30, 2022
  - Revenue: $65 million
  - Net income: Net loss of $2.7 million
  - EPS: $(0.03)
  - Guidance: raised
  - Result: reported results
  source text: Reger in newly created Chief Information Officer role and Cristina Green as Vice President of Clinical Research Third Quarter 2022 Financial Highlights • Consolidated revenue of $65 million, an increase of 24.3% from $52 million for the prior year quarter • Gross profit of $13 million, an increase of 13.8% compared to the prior year quarter • Net loss of $2.7
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/0001628280-22-029221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.